U.S. Senator Josh Hawley of Missouri grilled Federal Bureau of Investigation Director Kash Patel during a Senate hearing on Danco Laboratories, the Texas-based firm responsible for manufacturing and distributing Mifeprex, the FDA-approved abortion pill containing mifepristone. The questioning centered on whether Danco's practices — particularly its mailing of the medication across state lines — violate federal statutes and undermine state-level abortion restrictions.
Hawley alleged that Danco operates with financial backing from networks associated with billionaire philanthropist George Soros, who has been repeatedly linked by critics to organizations supporting reproductive rights and abortion access nationwide. While specific documentation tying Soros directly to Danco was not presented during the hearing, the questioner framed the company's cross-border mailings as a deliberate effort to bypass state laws restricting or banning the procedure.
The senator also pressed Patel on whether the FBI is reviewing potential violations of federal mail laws and interstate drug-distribution regulations in connection with Danco's operations. Under current federal law, mifepristone can be prescribed and mailed across state lines following a 2021 FDA ruling, but several states have passed legislation attempting to block the drug's distribution within their borders. The legal tension between state bans and federal pharmacy regulations remains unresolved in multiple courts.
Danco Laboratories, founded in 1998, has been a primary supplier of mifepristone in the United States. The company supplies the medication to clinics, telehealth providers, and individual prescribers who ship pills directly to patients. Its business model has drawn scrutiny from anti-abortion advocates, who argue the company is effectively operating an underground distribution network after the Supreme Court's 2022 Dobbs decision returned abortion regulation to the states.
FBI Director Patel did not provide detailed answers on whether any formal investigation into Danco was underway, but acknowledged that the bureau monitors activities involving the illegal distribution of regulated pharmaceuticals across state lines. Legal experts note that prosecuting a company for mailing FDA-approved drugs under existing federal authority could raise significant constitutional and statutory questions.
The hearing comes amid a broader national debate over the accessibility of medication abortion, which accounts for more than half of all U.S. abortions. Several Republican-led states have challenged the FDA's approval of mifepristone, while abortion-rights groups argue that restricting mail-order access infringes on patient rights and medical care.
